Furthermore, our study revealed that inhibiting the N-glycosylation of ACTRIIB can reduce the protein levels, decrease cellular proliferation, and enhance NPC cell sensitivity to docetaxel. The gene discussed is ACVR2B; the disease is nasopharyngeal carcinoma.